Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jean-Jacques Lafitte"'
Autor:
Thierry Berghmans, Arnaud Scherpereel, Anne-Pascale Meert, Vicente Giner, Jacques Lecomte, Jean-Jacques Lafitte, Nathalie Leclercq, Marianne Paesmans, Jean-Paul Sculier, for the European Lung Cancer Working Party (ELCWP)
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
IntroductionIn a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57–0.66] and for those including etoposide (HR 0.65; 0.61–0.69). That benefit was mai
Externí odkaz:
https://doaj.org/article/def77f8f82b74a1db40ee3da9b8c1674
Autor:
Thierry Berghmans, Jean-Jacques Lafitte, Arnaud Scherpereel, Lieveke Ameye, Marianne Paesmans, Anne-Pascale Meert, Benoit Colinet, Christian Tulippe, Luc Willems, Nathalie Leclercq, Jean-Paul Sculier, for the European Lung Cancer Working Party
Publikováno v:
ERS Monograph, 1 (2
ERJ Open Research
ERJ Open Research, Vol 1, Iss 2 (2015)
ERJ Open Research
ERJ Open Research, Vol 1, Iss 2 (2015)
Salvage chemotherapy (CT) for relapsing or refractory small cell lung cancer (SCLC) remains disappointing. In vitro experiments showed that valproic acid increases apoptosis of SCLC cell lines exposed to doxorubicin, vindesine and bis(2-chloroethyl)a
Autor:
Luigi Moretti, Anne-Pascale Meert, Nicolas Girard, Jean-Jacques Lafitte, Christiane Jungels, Valérie Durieux, Martine Roelandts, Thierry Berghmans, Stéphane Holbrechts, Sebahat Ocak
Publikováno v:
Lung cancer, Vol. 126, p. 25-31 (2018)
Thymic tumours are rare diseases that for most of the cases are cured with surgery and eventually adjuvant radiotherapy. However, about 30% of patients present with advanced stage or relapsing tumours, which require administration of chemotherapy. Wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff8b4447e4ba813e9f746a0510da31d4
https://hdl.handle.net/2078.1/208839
https://hdl.handle.net/2078.1/208839
Autor:
Arnaud Scherpereel, Thierry Berghmans, Jean-Paul Sculier, Marianne Paesmans, Jean-Jacques Lafitte, Anne-Pascale Meert, Nathalie Leclercq, Jacques Lecomte, V. Giner
Publikováno v:
11.1 Lung Cancer.
In a meta-analysis of the literature (Lung Cancer 30: 23-36; 2000), we showed survival benefits for regimens including cisplatin (Hazard ratio HR 0.61; 95 % CI, 0.57–0.66) and for those including etoposide (HR 0.65; 0.61–0.69).That benefit was ma
Autor:
Jean-Jacques Lafitte, Gregory Petyt, Stefanie Habib, Julie Delourme, Alexis B. Cortot, Nunzia Tacelli, Arnaud Scherpereel, Xavier Dhalluin
Publikováno v:
Lung Cancer. 80:197-202
Background Combination of bevacizumab and weekly paclitaxel showed synergitic effects, anti-tumor efficacy and a good toxicity profile for patients with breast cancer but has never been evaluated in non small cell lung cancer (NSCLC). We retrospectiv
Autor:
Anne-Pascale Meert, Olivier Van Cutsem, Vicente Giner, Martine Roelandts, Nathalie Leclercq, Yves Bonduelle, Arnaud Scherpereel, Thierry Berghmans, Benoit Colinet, Jean-Paul Sculier, Jean-Jacques Lafitte, Paul Van Houtte, Marianne Paesmans
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 117
Objectives To assess if induction radiochemotherapy followed by consolidation chemotherapy (arm A) will improve survival in comparison with the same chemotherapy given as induction followed by consolidation concurrent radiochemotherapy (arm B) in pat
Autor:
Anne-Pascale Meert, Jean-Paul Sculier, Arnaud Scherpereel, Thierry Berghmans, Jean-Jacques Lafitte, Christiane Jungels
Publikováno v:
Revue des Maladies Respiratoires. 29(1):21-27
RésuméIntroductionDes études d’enregistrement ont montré l’efficacité du pémétrexed dans les cancers bronchiques non à petites cellules (CBNPC), tant en combinaison en première ligne qu’en monothérapie en traitement de rattrapage. Le
Autor:
Thierry, Berghmans, Delphine, Gourcerol, Jean-Jacques, Lafitte, Katerina, Kotsori, Marianne, Paesmans, Arnaud, Scherpereel, Nathalie, Leclercq, Jean-Paul, Sculier, J P, Bervar
Publikováno v:
Lung Cancer. 61:378-384
Summary We aimed to evaluate, in a phase II study, the efficacy of the mitomycin–vinorelbine combination in non-small cell lung cancer (NSCLC) patients, relapsing after taxane-based regimens, a situation in which no standard chemotherapy is current
Autor:
Jean-Jacques Lafitte, Lieveke Ameye, Ingrid CsToth, Nathalie Leclercq, Luc Willems, Jean-Paul Sculier, Tiffany Dernies, Stéphane Holbrechts, Marianne Paesmans, Christian Tulippe, Anne-Pascale Meert, Jacques Lecomte, Michel Richez, Céline Mascaux, Arnaud Scherpereel, Thierry Berghmans, Benoit Colinet, Alexis B. Cortot
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 4 (2015)
Frontiers in oncology, 4
Frontiers in Oncology, Vol 4 (2015)
Frontiers in oncology, 4
Aim: Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung cancer (NSCLC), without accurate predictor for response and survival, but important toxicity. Our aims were to identify predictive (for response) and prognostic
Autor:
P Recloux, O Van Cutsem, Jean-Paul Sculier, Michel Richez, Jean-Jacques Lafitte, Vincent Ninane, Marianne Paesmans, Thierry Berghmans, Jean Klastersky, Paul Mommen
Publikováno v:
Lung Cancer. 37:73-77
The purpose of this study was to determine the activity of paclitaxel as a second-line chemotherapy for non-small cell lung cancer (NSCLC). This multicentric trial included patients who had failed to a first-line chemotherapy with platinum derivative